Kornimate/medical-research-clean huggingface dataset:
texting to reduce human immunodeficiency virus (hiv) risk

Conditions: HIV Infections

Summary: this is a 3-year study to test the efficacy of a text message-based intervention program. dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (tms) regarding hiv prevention or tms regarding overall wellness. prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the tm delivery as well as all study procedures. for both the pilot and the randomized clinical trial (rct), recruitment will be conducted at 4 community health center dental clinics (codman square, east boston (both east boston and south end locations), geiger gibson, and upham's community health centers). recruitment materials (flyers and permission to contact forms) may also be made available at other clinics within the health centers. the study will enroll english and spanish-speaking patients who have at least one risk factor for hiv but are hiv-negative. patients enrolled in the pilot will complete self-report surveys at baseline, 1 and 2 months. participants enrolled in the rct will complete self-report surveys baseline, 3, 6, and 12 months after baseline; receive and respond to tm assessments during the 6-month intervention.


Eligibility criteria:
inclusion criteria: * give informed consent and document consent via a signed and dated informed consent form in redcap * willing to comply with all study procedures and be available for the duration of the study * be able to read either in english or spanish * be a dental clinic patient of record at one of our participating community health centers * has at least one risk factor for hiv defined as self-report of at least one of the following: men who have sex with men; multiple sex partners, or intravenous drug use exclusion criteria: * self-report of having hiv infection * participating in another hiv study or another text message study * a woman who reports having sex exclusively with women * does not have a mobile phone or other device which can receive text messages from agile health * does not have unlimited texting on their mobile plan * has not used any type of text messaging at least once in the past month * single item literacy screening score of 2 or below.

Keywords: dental patients community health center dental clinics text messaging hiv negative hiv testing
down-titration of steroids in patients with difficult asthma with no bronchial hyperreactivity

Conditions: Asthma

Summary: an 8 week 'real-life' inhaled corticosteroid (ics) dose reduction study in patients with severe asthma without evidence of bronchial hyperactivity.

we aim to describe the proportion of patients with severe asthma, but without objective evidence of active disease, who can successfully be reduced in ics dose for a period of 8 weeks. this is also intended as an exploration of the methodology and feasibility of step-down studies with this patient group, to act as a pilot for future projects. this study enrolled patients from the sats severe asthma study, in which they had undergone systematic investigation for comorbidities, triggers and barriers to good asthma control. after baseline investigations, the patient's ics dose is halved (or as close as possible to, but not below, 50%). patients continued on the same inhaled steroid drug and device. patients taking a combined ics/laba inhaler halve the dose of this, as per usual clinical practice. other asthma medicaitons are continued unchanged.

Eligibility criteria:
inclusion criteria: * physician-diagnosed asthma for at least 6 months * fulfill ers/ats giudelines for severe asthma * stable dose of ics for at least 4 weeks * able to carry out study procedures * negative metacholine provocation test at screening * negative reversibility to beta agonist at screening * feno under 50 ppb exclusion criteria: * treatment with prednisolone, methotrexate, ciclosporin, omalizumab or nucala in the last 6 months * fev1 under 70% of predicted * acute upper or lower airway infection requiring antibiotics in the last 4 weeks * exacerbation of asthma requiring prednisolone in the last 6 months * current smoking * pregnancy or breastfeeding * other clinically significant lung disease * current participation in another interventional study
myspine mc versus myspine standard

Conditions: Degenerative Disc Disease; Osteochondrosis; Spondylolysis Lumbar

Summary: this research project compares the clinical performance of the cortical bone trajectory cbt insertion technique with the current clinical gold standard, the pedicle screw insertion technique. both techniques are performed by aid of myspine patient-specific guide systems.

adult subjects, among those whose clinical condition makes them eligible for a spinal stabilization and meeting the inclusion/exclusion criteria, will be invited to participate to the research project and ask to sign a consent in order to further use of personal and clinical data collected during standard practice visit. the primary objective of the research project is to compare clinical outcomes, in terms of assessing the main outcomes of importance to patients with back problems (pain, function, symptom-specific well-being, quality of life, disability), of spine surgery with cortical bone trajectory screw placement technique respect the traditional pedicle screw placement technique. preoperative data and collected during visit as per standard routine at 6 weeks, 3, 6 and 12 months postop will be recoreded and assessed for the purpose of this research project.

Eligibility criteria:
inclusion criteria: 1. patients affected by degenerative disc disease, osteochondrosis and grade i spondylolisthesis needing a one/two level surgical treatment with posterior approach and screw fixation 2. those who need a surgical procedure of lumbar spine stabilization from level l1 to level l5. 3. patients who are willing and able to provide written informed consent for participation in the study. written informed consent must be obtained prior to the patient's surgery 4. healthy patients or patients with mild or severe systemic disease identified as patients with asa score 1, 2 or 3. 5. patients with bmi ≤ 35 kg/m2 6. non responsive or insufficient response to conservative treatment. exclusion criteria: 1. patients presenting contraindications as defined by medacta instruction for use 2. patients affected by lytic spondylolisthesis and degenerative spondylolisthesis with grade≥2 will be excluded 3. patients \<18 years 4. patients who are pregnant or intend to become pregnant during the study 5. known substance or alcohol abuse
relationship between d2 receptors spect and the apomorphine test in patients with oh dependence (alc-drd2-apo)

Conditions: Alcoholism

Summary: oh dependence is associated with da receptor changes. both, the apomorphine test and the d2rec spect are usefull for monitoring da receptor status. we aimed at studying whether da receptor hypofunction, assessed by means of the apomorphine test and the d2rec spect, is a marker of relapse in detoxified oh dependents patients.


Eligibility criteria:
inclusion criteria: * alcohol dependence * alcohol dependence length at least 8 years. * male * age 25 - 60 years exclusion criteria: * other drug dependence (except nicotine dependence) * another major axis i psychiatric diagnosis * comorbid neurological disorder * comorbid cardiovascular disorder * comorbid metabolic disorder * brain injury * apomorphine allergy * iode allergy * diazepam allergy

Keywords: alcoholism apomorphine iodobenzamide imaging spect relapse
randomized, double-blind, placebo-controlled trial of rel-1017 as adjunctive treatment for mdd

Conditions: Major Depressive Disorder; Depression

Summary: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial of rel-1017 in patients with major depressive disorder (mdd).

this is an outpatient, 2-arm, phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of rel-1017 once daily (qd) as an adjunctive treatment of major depressive disorder in patients with inadequate response to ongoing background antidepressant treatment. eligible patients will continue to take their background antidepressant therapy and be randomized in a 1:1 ratio to treatment with rel-1017 or placebo for a 4 week treatment period.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18.0 and 35.0 kg/m2. * diagnosed with major depressive disorder (mdd) based on structured clinical interview for dsm-5 (scid-5) for mdd. * inadequate response to 1 to 3 adequate antidepressant treatments in the current mde. exclusion criteria: * psychiatric hospitalization during the current major depressive episode. * history or presence of clinically significant health conditions which in the opinion of the investigator would negatively impact the safety of the participant. * participants who, in the investigator's judgment, are at significant risk for suicide. * pregnant or planning to become pregnant.

Keywords: rel-1017 esmethadone relmada antidepressant adjunctive nmda receptor antagonist relight depression
polish nationwide register of hospitalized patients in cardiac intensive care units

Conditions: Shock; Death; Cardiac Intensive Care Unit; Treatment Complication; Stroke; Multiple Organ Failure; Infections

Summary: cardiac intensive care units (cicus) provide care for a diverse patient population. understanding the clinical characteristics, analysis of treatment modalities, and prognosis of patients hospitalized in the cicu are important to improve cardiovascular care. the purpose of this registry is to determine the demographics, clinical, treatment, and prognosis of patients hospitalized in the polish cicus. data from this multicenter, prospective observational study will provide more robust data to facilitate quantitative characterization of cardiac care in contemporary polish cicus and enable the development of infrastructure for clinical trials in cicus.


Eligibility criteria:
all consecutive patients hospitalized at polish cicus.
the effect of motivational interviews on the digital game addiction levels of nursing students

Conditions: Motivational Interview; Addiction

Summary: the aim of this study is to reveal the effect of motivational interviewing based on change stages on digital game addiction. this study will be conducted with a total of 72 individuals assigned by a randomization site from all nursing students who study at sivas cumhuriyet university, faculty of health sciences, voluntarily participated in the study, and were found to be digital game addicts. these individuals will be equally distributed to the intervention and control groups. personal information form, stages of change questionnaire and digital game addiction scale will be distributed to individuals to answer. the obtained data will be analyzed statistically.

the aim of this study is to reveal the effect of motivational interviewing based on change stages on digital game addiction. this study will be conducted with a total of 72 individuals assigned by a randomization site from all nursing students who study at sivas cumhuriyet university, faculty of health sciences, voluntarily participated in the study, and were found to be digital game addicts. these individuals will be equally distributed to the intervention and control groups. each group will contain 36 participants. the participants in intervention group will take motivational interventions while the individuals who have digital game addiction in control group will not take this application. personal information form, stages of change questionnaire and digital game addiction scale will be distributed to individuals to answer. the obtained data will be analyzed statistically.

Eligibility criteria:
inclusion criteria: nursing students who: * agree to participate in the study * are over 18 years * have game addiction * agree to participate in the negotiations exclusion criteria: individuals who: * do not agree to participate in the study

Keywords: digital game addiction nursing study change stages motivational interview
epigenetics, vitamin c and abnormal hematopoiesis - pilot study

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia

Summary: this study evaluates whether vitamin c improves responses to epigenetic therapy with dnmtis. half of the patients will receive vitamin c and dnmti while the other half will receive placebo and dnmti.

recently, it was documented that hematological cancer patients with myelodysplastic syndrome (mds) or acute myeloid leukemia (aml) exhibited severe vitamin c deficiency. vitamin c is an essential co-factor for ten-eleven translocation (tet) enzymes, which initiate dna demethylation through oxidation of 5-methylcytosine (mc) to 5-hydroxy-methylcytosine (hmc). in-vitro studies show that vitamin c at physiological doses added to dna methyltransferase inhibitors (dnmtis), induce a synergistic inhibition of cell proliferation and enhanced apoptosis. these effects are mediated via a viral mimicry response recently associated with cancer stem-like cell death and enhanced immune signals including increased expression of bi-directionally transcribed endogenous retrovirus (erv) transcripts, increased presence of cytosolic double stranded rnas, and activation of an interferon inducing cellular response to these transcripts. data suggest that correction of vitamin c deficiency may improve responses to epigenetic therapy with dnmtis. in the evita pilot study, the investigators include mds/aml patients and explore the potential role of restoring vitamin c within the normal physiological range in treatment of hematological cancer with dnmtis.

Eligibility criteria:
inclusion criteria: * mds/aml patient in treatment with dnmti exclusion criteria: * intake of vitamin c as a dietary supplement including multivitamin * non-compliance
cardio protective effect of sgl2i in hemodialysis patients and its impact on patient quality of life

Conditions: Kidney Diseases

Summary: if this study has a cardio protective effect it will affect the mortality and morbidity of advanced ckd patients and improve their quality of life

cardiovascular disease is the leading cause of mortality, accounting for \>50% of deaths with known causes, while cardiovascular mortality is 9-fold higher in these patients compared with age- and sex-matched individuals in the general population particularly, heart failure poses a significant challenge in the management of eskd. it frequently develops after initiation of dialysis and is a prominent mortality risk factor among these patients when ckd patients develop hf, increased sodium and fluid retention, and vascular tension will lead to increased preload of the heart. the increased ventricular wall pressure will lead to release biomarkers like natriuretic peptides (np). therefore, biomarkers of myocardial stretch are commonly used in the diagnosis and prognosis evaluation of hf. it is worth noting that the negative predictive value of np is extremely high (0.94-0.98), while the positive predictive value is slightly lower, (0.44-0.57) for chronic heart failure (chf) and (0.66-0.67) for acute heart failure (ahf), commonly used myocardial stretch marker include nt-pro bnp . nt-pro bnp has the advantage that accuracy of negative diagnosis is extremely high; the prognostic value is the most powerful, especially in ckd stages 4-5 and dialysis patients traditional therapies to prevent cvd complications in the general population have shown to be ineffective in chronic kidney disease (ckd). to address the unmet need, further research is needed to evaluate novel therapeutic strategies to improve cardiovascular outcomes among patients on dialysis . over the last several years, sodium-glucose transporter type 2 (sglt2) inhibitors have been shown to confer substantial kidney and cardiovascular benefits among patients with type 2 diabetes, heart failure, and/or high-risk ckd . secondary analyses from these landmark trials demonstrated consistent benefits of sglt2 inhibitors across many subgroups, supporting the widespread use and incorporation in clinical practice guidelines of this new kidney and cardio protective drug class.

Eligibility criteria:
inclusion criteria: * patients with ckd stage5 (i.e., egfr \< 15 ml/min/1.73m2) (inker et al., 2021) exclusion criteria: * patients who refuse to sign consent * patients with acute heart failure , will exclude patients with known prior ischemic heart diseases or ischemic cardiomyopathy * autosomal dominant polycystic kidney disease (adpkd). * type 1 diabetes mellitus * history of ketoacidosis in the last year. * known hypersensitivity to sglt2 inhibitors. * known severe hepatic impairment (child-pugh class c) * pregnant or breastfeeding females
applying the use of motivational tools to auditory rehabilitation

Conditions: Hearing Loss

Summary: the purpose of this study is to compare two different ways of helping first-time hearing-aid users get the most out of their hearing aids and determine if one method is better than the other. one method provides the patient with routine information regarding the care and use of hearing aids the other method uses tools to address patient-specific barriers against and motivators for hearing-aid use.


Eligibility criteria:
inclusion criteria: * be aged between 20 and 89 years * be a first-time hearing-aid user * air-conduction pure-tone averages (mean thresholds at 500 hz, 1000 hz, and 2000 hz) of 70 db hl or less in both ears * word-recognition scores of 40% or better in each ear * english as their first language * have sufficient vision and reading ability * have the appropriate cognitive skills to participate in the study as determined by the mini mental state exam, 2nd edition - brief version (folstein et al., 2010) * have been fit by the va portland health care system audiology and speech pathology service (asps) with two hearing aids which have datalogging capabilities * be independent in their completion of activities in daily living, as determined by their score on the katz index of independence in activities of daily living (katz et al., 1970) * have poor adoption of their hearing aids * be free of a documented diagnosis in the va computerized patient record system (cprs) record of neurological or psychological disorder, such as alzheimer's disease, schizophrenia, or uncontrolled substance abuse, which would interfere with the completion of the study. vulnerable populations are not being studied. exclusion criteria: failure to satisfy any of the requirements listed as inclusion criteria

Keywords: hearing loss hearing aids motivational interviewing counseling rehabilitation
physiologic effects of rbc transfusion

Conditions: Red Blood Cell Transfusion

Summary: the purpose of this study is to determine how red blood cell transfusions, particularly the length of storage time of units of packed red blood cells, affects the cardiovascular function in patients receiving transfusions. this study will also determine the most ideal way of storing and processing blood, and assess how transfusion affects a person's ability to exercise and how their blood vessels relax and contract.

the purpose of this study is determine red blood cell transfusion, particularly the length of storage time of units of packed red blood cells, affects cardiovascular function in patients receiving transfusions. transfusion of red blood cells is often used clinically in patients with low red blood cell counts in order to prevent disease progression and death. recent studies suggest that the use of "aged" versus "fresh" red blood cells is associated with worse clinical outcomes, but there is no clear understanding on how this happens. the investigators want to determine the most ideal way of storing and processing blood, and learn how transfusion affects the ability to exercise in the study subjects and assess the relaxation and contraction of the blood vessels.

Eligibility criteria:
inclusion criteria: - subjects with any condition resulting in transfusion-dependent anemia exclusion criteria: * age \ 80 years * pregnancy * acute infection in previous 4 weeks * active substance abuse within the past year * inability to give informed consent * inability to return for follow-up * the presence of alloantibodies that would limit the blood bank's ability to obtain correctly aged red blood cell (rbc) units

Keywords: chronic anemia cardiopulmonary testing transfusion-dependent anemia
the efficacy and cognitive impairment of modified electroconvulsive therapy

Conditions: Major Depressive Disorder

Summary: 1. to determine the influencing factors of modified electroconvulsive therapy (mect); 2. to determine the influencing factors and reversibility of the cognitive impairment caused by mect; 3. to determine the duration of efficacy of mect and its affecting factors.


Eligibility criteria:
inclusion criteria: * aged over 18 years (when informed consent was got), male or female * meet international classification of diseases-10(icd-10) diagnostic criteria for depression * scored 18 or above on the ham-d scale which included 17 items * clinical global impression(cgi)-severity score ≥ 4 * provided written informed consent exclusion criteria: * any depressive disorders not due to major depressive disorder * meet other diagnosis criteria in diagnostic and statistical manual of mental disorders-iv-test revision(dsm-iv-tr) axis i * with a history of acute or chronic renal failure, liver cirrhosis or active hepatopathy * with clinically significant abnormal results of laboratory test, which are considered to have impact on treatment efficacy and the safety of participants * with a history of severe or unstable physical disease including nervous system disease and myocardial infarction * undergoing alcoholism or alcohol (or substance) abuse during 30 days or 6 months before the trial * with no response to previous ect treatment * received transcranial magnetic stimulation treatment in the last 6 months * allergic to propofol, etomidate and succinylcholine chloride * during pregnancy or lactation * with a history of stroke in the last month * enrolled in any other clinical trial 30 days prior to the baseline

Keywords: major depressive disorder modified electroconvulsive therapy cognition memory